Morroniside (MOR) inhibits the progression of NASH by promoting AMPK-dependent lipophagy and inhibiting NLRP3 inflammasome activation (Zhang et al., 2024). This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatohepatitis.